Fortress Biotech Inc (FBIO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.84-6.60%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · FBIO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -89.6% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 54.5% |
Growth built into the price is above our model estimate.
The price assumes 144.1 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name has erratic recent earnings surprises and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
FBIO — credit agreement
Dated 2026-10-01
Other Events. As previously disclosed, on July 25, 2024, Fortress Biotech, Inc. (the “ Company ”), as borrower, entered into a $50.0 million senior secured credit agreement (as amended on December 12, 2025 and February 22, 2026, the “ Oaktree Agreement ”) with Oaktree Fund Administration, LLC and the lenders from time-to-time party thereto. On September 30, 2026, the Company repaid in full the remaining $15.0 million in outstanding principal under the facility, together with approximately $…
Why it matters: The two global trials are key steps toward a possible royalty stream. Slow enrollment or a trial delay would push that path back.
Watch forCrystalys reports that both Phase 3 trials remain open and enrollment is advancing, with no delay to the trial plan.
Also watch forCrystalys reports a pause, delay, or end to either Phase 3 trial.
Why it matters: The planned CMV data could show whether this program has promise in patients with HIV and CMV.
Watch forFortress or its partner releases the planned Triplex data by December 31, 2026. It reports that the study met its stated goals.
Also watch forThe data miss the stated goals, or no readout is reported by December 31, 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$202 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $514 loss on $10,000 · 5.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,987 loss on $10,000 · 49.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.